Skip to main content
. 2018 Mar 27;9(23):16573–16587. doi: 10.18632/oncotarget.24654

Table 2. Summary of urinary proteomic biomarkers proposed for the management of pancreatic cancer.

Single biomarker or panel Utility Expression patterna Impact in prognosis Year Ref.
LYVE-1, REG-1-alpha, and TFF-1 Diagnostic All ↑ - 2015 [101]
D-dimer Preoperative resectability Negative 2014 [102]

a Expression pattern observed in pancreatic cancer patients. ↑: upregulated. ↓ downregulated.